| scholarly article | Q13442814 |
| P50 | author | Anca Askanase | Q91519987 |
| P2093 | author name string | Enxu Zhao | |
| Richard A Furie | |||
| Erin Connolly-Strong | |||
| Julie Zhu | |||
| P2860 | cites work | ACTH protects against glucocorticoid-induced osteonecrosis of bone | Q24631407 |
| Astrocytes: new targets of melanocortin 4 receptor actions | Q26865387 | ||
| Systemic lupus erythematosus. | Q53202066 | ||
| The melanocortin system in control of inflammation. | Q55426694 | ||
| Advances in the treatment of Systemic Lupus Erythematosus: from back to the future, to the future and beyond | Q57154870 | ||
| Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus | Q87556958 | ||
| Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus | Q87740032 | ||
| A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus | Q28254310 | ||
| ACTH: The forgotten therapy | Q28258012 | ||
| Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial | Q28304807 | ||
| Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study | Q33698040 | ||
| Numerical scoring for the BILAG-2004 index | Q34056232 | ||
| Targeting melanocortin receptors as a novel strategy to control inflammation. | Q35682900 | ||
| Direct effects of HP Acthar Gel on human B lymphocyte activation in vitro | Q36218750 | ||
| Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis | Q36613389 | ||
| Corticosteroids: do they damage the cardiovascular system? | Q36679823 | ||
| Curbing Inflammation through Endogenous Pathways: Focus on Melanocortin Peptides | Q36877176 | ||
| Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study | Q37464041 | ||
| Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials | Q37633396 | ||
| Clinical practice. Glucocorticoid-induced bone disease | Q37898140 | ||
| Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. | Q39150632 | ||
| Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength | Q40604863 | ||
| Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome | Q44807843 | ||
| A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea | Q49359821 | ||
| Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study | Q49480873 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | placebo | Q269829 |
| multicenter clinical trial | Q6934595 | ||
| placebo-controlled trial | Q108853737 | ||
| P304 | page(s) | e000383 | |
| P577 | publication date | 2020-04-21 | |
| P1433 | published in | Lupus science & medicine | Q27725658 |
| P1476 | title | Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial | |
| P478 | volume | 7 |
Search more.